文献速递青光眼

Cromakalim前药1(CKLP1)对房水动力学的影响及与现有降眼压药物联合治疗的可行性

Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

CKLP1是一种水溶性ATP敏感性钾通道开放剂,在离体和在体实验模型中已显示降眼压特性。本研究通过小鼠离体眼灌注和在体恒流灌注评估CKLP1对房水动力学的影响,并在无小梁网的人眼前节段评估其降压效果。结果表明CKLP1通过降低巩膜外静脉压和降低传统流出通路远端阻力来降低眼压,并与拉坦前列素、噻吗洛尔和Rho激酶抑制剂Y27632呈相加作用降低眼压。

要点

  • CKLP1降低巩膜外静脉压(对照组8.9±0.1 mmHg vs 治疗组6.2±0.1 mmHg,P<0.0001),对流出易度、房水生成率或葡萄膜巩膜流出无 detectable 影响。
  • 在无小梁网的人眼前节段中,CKLP1治疗导致压力下降50%±9%,提示作用于传统流出通路远端。
  • CKLP1与拉坦前列素、噻吗洛尔和Y27632联合降眼压呈相加作用,推测因对房水动力学不同方面的联合效应。

核心结论

  • CKLP1通过降低巩膜外静脉压和降低传统流出通路远端阻力来降低眼压。
  • 由于这一独特作用机制,CKLP1与拉坦前列素、噻吗洛尔和Rho激酶抑制剂Y27632以相加方式降低眼压。

研究设计与样本

  • 在C57BL/6小鼠中通过离体眼灌注和在体恒流灌注评估流出易度。
  • 在无小梁网的人眼前节段中评估CKLP1治疗后的压力效应。
  • 在C57BL/6小鼠和Dutch-belted色素兔中评估CKLP1单用及与拉坦前列素、噻吗洛尔和Rho激酶抑制剂Y27632联用对眼压的影响。

主要发现

  • CKLP1降低巩膜外静脉压(对照组8.9±0.1 mmHg vs 治疗组6.2±0.1 mmHg,P<0.0001)。
  • CKLP1对流出易度、房水生成率或葡萄膜巩膜流出无 detectable 影响。
  • 在无小梁网的人眼前节段中,CKLP1治疗导致压力下降50%±9%。
  • CKLP1与拉坦前列素、噻吗洛尔和Y27632联合降眼压呈相加作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cromakalim prodrug 1 (CKLP1) is a water-soluble ATP-sensitive potassium channel opener that has shown ocular hypotensive properties in ex vivo and in vivo experimental models. To determine its mechanism of action, we assessed the effect of CKLP1 on aqueous humor dynamics and in combination therapy with existing ocular hypotensive agents. METHODS: Outflow facility was assessed in C57BL/6 mice by ex vivo eye perfusions and by in vivo constant flow infusion following CKLP1 treatment. Human anterior segments with no trabecular meshwork were evaluated for effect on pressure following CKLP1 treatment. CKLP1 alone and in combination with latanoprost, timolol, and Rho kinase inhibitor Y27632 were evaluated for effect on intraocular pressure in C57BL/6 mice and Dutch-belted pigmented rabbits. RESULTS: CKLP1 lowered episcleral venous pressure (control: 8.9 ± 0.1 mm Hg versus treated: 6.2 ± 0.1 mm Hg, P < 0.0001) but had no detectable effect on outflow facility, aqueous humor flow rate, or uveoscleral outflow. Treatment with CKLP1 in human anterior segments without the trabecular meshwork resulted in a 50% ± 9% decrease in pressure, suggesting an effect on the distal portion of the conventional outflow pathway. CKLP1 worked additively with latanoprost, timolol, and Y27632 to lower IOP, presumably owing to combined effects on different aspects of aqueous humor dynamics. CONCLUSIONS: CKLP1 lowered intraocular pressure by reducing episcleral venous pressure and lowering distal outflow resistance in the conventional outflow pathway. Owing to this unique mechanism of action, CKLP1 works in an additive manner to lower intraocular pressure with latanoprost, timolol, and Rho kinase inhibitor Y27632.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Roy Chowdhury U, Rinkoski TA, Bahler CK, et al. Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents. Invest Ophthalmol Vis Sci. 2017. PMID: 29114841. doi:10.1167/iovs.17-22538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。